The Next Pricing Frontier: What IRA, MFN and Policy Reform Mean for Biopharma

Jennifer Snow is the founder of Apteka Policy, where she translates U.S. pharmaceutical policy into strategic clarity for drug manufacturers, coalitions, and advocacy organizations. Her work spans drug pricing, Medicare, Medicaid, 340B, the IRA, and PBMs with a focus on what leaders need to act on and what they can safely ignore.

Jennifer brings a rare cross-sector perspective: she has carved out PBMs at Stanford, drafted regulations at CMS, shaped commercial strategy at AstraZeneca, and built client strategy at Avalere and Xcenda. That range is the point, she knows how pharmaceutical policy looks from every seat at the table.

Jayson S. Slotnik is a Principal and founding member of Health Policy Strategies, Inc., a Washington, D.C. based consulting firm representing innovative biotech, pharmaceutical, device, and diagnostic companies. Jayson specializes in, and counsels clients on, the impact that Medicare and Medicaid coverage, payment, reimbursement, coding, and government policies have on commercial success. He also has experience as a healthcare strategist with demonstrated success in developing and implementing both pre- and post-launch strategies as well as life cycle management tools for pharmaceutical, biotechnology, diagnostic, and device manufacturers.

Paul Battagliais Chief Operating Officer of Elusa Health and a patient services leader with more than 25 years of experience across pharmaceutical access and patient support. Having built and led programs from the front line through executive leadership roles at TheraCom, Lash Group, Two Labs and Elusa Health, Paul brings a unique combination of operational and strategic perspective. Throughout his career, he has helped pharmaceutical and biotech companies design, evaluate and optimize patient services programs across specialty and rare disease. His focus is on turning program strategy into operational execution that reduces barriers to therapy, improves the patient and provider experience, and delivers measurable value for manufacturers.

Dee Chaudhary is a Principal with Clarivate’s Commercial Strategy Consulting practice with 20+ years of experience in life science consulting and the biopharmaceutical industry. Primarily focused on health policy, launch readiness and market access strategy in the urology, immunology and oncology space, she is experienced in pricing and launch strategy, reimbursement, product positioning, payer value messaging and patient journey.

Dee has led multiple projects with a broad range of TAs. Her work as a subject matter expert in Medicare and Government Payers has resulted in podium speaking opportunities at Asembia, multiple webinar panel engagements and publication in US News and World Report. Prior to joining Clarivate, Dee held leadership roles at biopharma organizations and consulting firms, including the National Director of Market Access, Reimbursement & Trade for a buy-and-bill urology/oncology product and Senior Director of Customer Satisfaction. Dee has a Masters in Healthcare Administration and a BA in History and French.

Matthew Arnold serves as a Research Analyst and Content Strategist. He joined Clarivate after covering the life science industries as a Journalist for more than a decade and has followed pharma and medtech from the dawn of DTC advertising and mass-market blockbusters to the age of genetic medicine and surgical robotics.

Over her ten plus year tenure with Clarivate, Mannat has worked to deliver strategic and actionable insights to pharmaceutical and biotech companies through engagements focused on commercialization, market and product opportunity assessments, value proposition development, therapeutic area strategy, pricing and contracting strategy and account profiling engagements in the neurology, immune/inflammatory, rare disease, and oncology space.​ Prior to joining Clarivate, Mannat worked at the Center for Bioactive Materials and Tissue Engineering at the University of Pennsylvania as a Research Assistant. Her work included developing a controlled drug delivery system using silica nanoparticles. Mannat also interned at DocASAP where she collaborated with teams at WebMD, UnitedHealthcare and Planned Parenthood to create functional specifications for Next Generation work flows. ​Mannat has a Masters in Biotechnology from the University of Pennsylvania where she worked on a research project studying the innovations across different industries, with a focus on Healthcare.​